Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection

Next Previous
X
Search
Trial Profile

A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimodivir (Primary) ; Antivirals
  • Indications Influenza A virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms SAPPHIRE
  • Sponsors Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 09 Oct 2020 This trial has been completed in the United Kingdom according to European Clinical Trials Database record.
    • 13 Sep 2020 This trial has been completed in Belgium according to European Clinical Trials Database record.
    • 02 Sep 2020 According to a Janssen media release, company discontinued development of pimodivir for the treatment of influenza A infection. This decision is based on results from pre-planned interim analyses of the pimodivir phase III trial in hospitalized patients with influenza A. Pimodivir in combination with the standard of care (SOC) fails to demonstrate added benefit in hospitalized patients with influenza A compared to SOC treatment alone.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top